Abstract:Background: In males with end stage renal disease biochemical hypogonadism is a frequent finding. Testosterone and sex hormone binding globulin (SHBG) have been associated with insulin resistance, a well-known condition in uremia. The aim of the present study was to investigate in males on chronic hemodialysis the relationship of testosterone and SHBG serum levels with insulin resistance. Methods: In a cross-sectional study we enrolled men treated with chronic hemodialysis who did not suffer from an acute illness or other endocrinopathy, as well as primary hypogonadism, and were not hospitalised. Diabetes mellitus, diabetic nephropathy or previous transplantation were not exclusion criteria. As controls we used a community-based group of healthy males matched for age and Body Mass Index (BMI). We assessed the BMI (kg/m2) from body weight and height, the body fat content (%) by bioelectrical impedance and serum testosterone (ng/ml), SHBG (nmol/L) and estradiol (pg/ml) by standard methods. Testosterone < 3.25 ng/ml defined biochemical hypogonadism. In non-diabetic males, we calculated the homeostasis model assessment index (HOMA-R), an estimate of insulin resistance, from serum fasting insulin and glucose. Results: 27 men (age 54.4 ± 19 years) on chronic hemodialysis (treatment duration 29.1 ± 14.4 months) and 51 healthy men (age 47.1 ± 9.6 years) were included. In men on hemodialysis vs. healthy men there were increased serum levels of SHBG (40.9 ± 26.9 vs. 27.6 ± 11.9 nmol/L; p = 0.031) and a significantly enhanced frequency of biochemical hypogonadism (22.2 vs. 3.9%; p = 0.011). In cases without diabetes (n = 22) a significant correlation was observed between the HOMA-R (r = -0.586, p = 0.004) and the fasting insulin levels (r = -0.650, p = 0.001) on the one hand and the serum SHBG levels on the other. Conclusions: Our findings confirm enhanced prevalence of biochemical hypogonadism in males on chronic hemodialysis. In non-diabetic cases the serum levels of SHBG correlated with serum insulin and insulin resistance.

Hyperprolactinaemia and testosterone production. Observations in 2 men on long-term dialysis

Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis

Successful gonadotrophin treatment of hypogonadism in postoperative patients with macroprolactinoma and persistent hyperprolactinaemia

Hyperprolactinemia in men: clinical and biochemical features and response to treatment

[Prolactinoma in the male. Physiopathological, clinical, and therapeutic features]

Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia

[Hyperprolactinemia and sexual activity of men--clinical aspect]

Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

Impact of Kidney Transplantation on Reproductive Hormone Levels in Males: A Longitudinal Study

Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma

Endocrine assessment of impotence--pitfalls of measuring serum testosterone without sex-hormone-binding globulin

Treatment of sexual dysfunction induced by hyperprolactinemia accompanied by reduced luteinizing hormone levels: A case report

Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy

Sex hormone binding globulin (SHBG) serum levels and insulin resistance in men on chronic hemodialysis

[Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction]

[Erectile dysfunction secondary to hyperprolactinemia. Apropos of 13 cases]

Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor

Hyperprolactinaemia: analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital

Long-term follow-up of 246 hyperprolactinemic patients

Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism